April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
AAV5-mediated gene therapy rescue cone function in a mouse model of achromatopsia
Author Affiliations & Notes
  • Xiaofang Liang
    PUMCH, Beijing, China
    Peking Union Medical College, Beijing, China
  • Fangtian Dong
    PUMCH, Beijing, China
    Peking Union Medical College, Beijing, China
  • Huajin Li
    PUMCH, Beijing, China
    Peking Union Medical College, Beijing, China
  • Qi Zhou
    PUMCH, Beijing, China
    Peking Union Medical College, Beijing, China
  • Lizhu Yang
    PUMCH, Beijing, China
    Peking Union Medical College, Beijing, China
  • Jijing Pang
    University of Florida, Gainesville, FL
  • Ruifang Sui
    PUMCH, Beijing, China
    Peking Union Medical College, Beijing, China
  • Footnotes
    Commercial Relationships Xiaofang Liang, None; Fangtian Dong, None; Huajin Li, None; Qi Zhou, None; Lizhu Yang, None; Jijing Pang, None; Ruifang Sui, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3319. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiaofang Liang, Fangtian Dong, Huajin Li, Qi Zhou, Lizhu Yang, Jijing Pang, Ruifang Sui; AAV5-mediated gene therapy rescue cone function in a mouse model of achromatopsia. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3319.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To clarify whether AAV5 vector-mediated gene therapy could restore cone function in the cnga3cpfl5 mouse model of achromatopsia.

 
Methods
 

AAV5-IRBP/ GNAT2-hCNGA3 were injected subretinally into one eye of mice at postnatal day 21. The mice that had more than 80% retinal detachment and minimal complications after surgery were kept for follow-up experiments. Contralateral eyes were uninjected as controls. Electroretinographic were recorded to detect cone response at 170 days after treating. Then eyes were enucleated after sacrifice and prepared for cryosections. Opsins expression of retina were conducted with immunofluorescence using S-opsins and M-opsins as primary antibodies.

 
Results
 

Compared with the untreated eyes, AAV5 mediated gene therapy could rescue cone response evidently. Both M- and S-opsins were expressed in outer segment of the retina. The curative effect of gene therapy for cnga3cpfl5 lasted for at least 170 days after injection.

 
Conclusions
 

In this study, the time of gene therapy a week later usual postnatal 14 days, but we show that therapeutic effect is also distinct in a naturally occurring mouse model of CNGA3 achromatopsia. The results provide us the illumination for future AAV5-based gene therapy for human CNGA3 achromatopsia.

 
Keywords: 538 gene transfer/gene therapy • 539 genetics  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×